Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)
To compare the effects and safety of Anlotinib with placebo in patients with Medullary Thyroid Carcinoma.
Medullary Thyroid Carcinoma
DRUG: Anlotinib|DRUG: Placebo
Progression-free Survival (PFS), To compare the Progression-free Survival (PFS) of subjects with medullary thyroid carcinoma(MTC) with Anlotinib versus Placebo., Date of randomization to the date of disease progression (measured every 6 weeks) or death (whichever occurs first) as determined by blinded independent imaging review(assessed up to 24 months)
Overall Response Rate (ORR), To compare Overall Response Rate (ORR) (Complete and Partial Responses, CR and PR) of subjects treated with Anlotinib versus Placebo., Date of randomization to the date of disease progression (measured every 6 weeks) or death (assessed up to 24 months)
To compare the effects and safety of Anlotinib with placebo in patients with Medullary Thyroid Carcinoma.